WHWK Insider Caley Castelein Buys 38,040 Shares
Insider Caley Castelein bought 38,040 shares of Whitehawk Therapeutics on June 12, 2026, amid growing analyst interest.
Reviewed by automated data checks against the source filing. How we make and check alerts
Caley Castelein bought 38,040 shares of Whitehawk Therapeutics, Inc. ($WHWK) on June 12, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $WHWK is up 7.2% after 1 week, down 7.7% after 1 month and down 30.5% to date (from the $4.16 close on Jun 12, 2026).
WHWK
Whitehawk Therapeutics, Inc.
Key Points
- Caley Castelein purchased 38,040 shares of Whitehawk Therapeutics on June 12, 2026, with the stock trading around $4.10 at the time.
- The company's stock has a 52-week range of $1.82 to $5.50, reflecting its volatility in the biotechnology sector.
- Analysts have recently shown positive sentiment, with B. Riley Securities initiating coverage with a Buy rating and a $10 price target.
Get $WHWK trade alerts by text
We text you when insiders, Congress or big funds trade $WHWK. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Whitehawk Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Whitehawk Therapeutics, Inc.
On June 12, 2026, Caley Castelein bought 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK). The stock was trading at approximately $4.10 at the time of the purchase. This acquisition is part of a broader trend of insider buying within the company, indicating confidence in its future prospects.
Multiple Insiders Buy Shares
Castelein wasn't the only insider to make a move on June 12. Mohammad Hirmand, Behzad Aghazadeh, Baiteng Zhao, Richard Maroun, Emma Reeve, and Neil Desai all purchased 38,040 shares each on the same day. This collective buying action suggests a strong belief among the leadership in the company's direction and potential growth.
Analysts Set New Price Targets
Analysts are taking notice of Whitehawk Therapeutics as well. On June 25, 2026, B. Riley Securities initiated coverage with a Buy rating and a $10 price target. Following that, Leerink Partners also initiated coverage on July 13, 2026, rating it as Outperform with a $9.00 target. Stifel joined the chorus on October 1, 2026, initiating a Buy rating, also with a $9.00 price target. These ratings contribute to a positive outlook for the stock, which has a mean target price of $7.50 based on six analyst opinions.
Stock Performance Context
As of the latest data, Whitehawk's stock trades close to its 52-week high of $5.50, with a recent close at $4.20. The stock has shown some volatility, having a 52-week low of $1.82. This performance highlights the stock's potential for growth, especially with the recent insider purchases and favorable analyst ratings.
Upcoming Earnings
Whitehawk Therapeutics is scheduled to report its next earnings on November 5, 2026. Investors will be watching closely to see how the company performs financially, especially in light of the recent insider confidence and analyst support.
What Whitehawk Therapeutics, Inc. Does
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company based in Morristown, New Jersey. It focuses on developing innovative therapies for cancer treatment, specifically through next-generation antibody drug conjugates. The recent insider activity suggests that the leadership is optimistic about the company's future and its pipeline of oncology therapeutics.
What's Ahead for Whitehawk Therapeutics, Inc.
With several insiders recently buying shares, and analysts providing positive ratings, Whitehawk Therapeutics is in the spotlight. Investors will be keen to see the upcoming earnings report and any further developments in the company's clinical trials and product pipeline.
Related Filing Alerts
Source: Caley Castelein's Form 4 filing on $WHWK (Jun 12, 2026). Find the original filing: WHWK Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts